OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BIOEX55

Bioextrax AB publ

Environmental Services & EquipmentVerified

Bioextrax operates with a debt-free capital structure, as evidenced by a debt-to-equity ratio of 0.0. The company holds SEK 3.93 million in cash and equivalents, but its operating cash flow is negative at SEK -26.05 million, indicating a reliance on external financing or asset sales to fund operations. The current ratio of 1.58 suggests the company can cover its short-term liabilities with its current assets, but the negative free cash flow of SEK -16.73 million raises concerns about long-term liquidity. Profitability metrics are severely negative, with a return on equity of -83.46% and a return on assets of -71.6%. These figures are well below the typical thresholds for sustainability in the Environmental Services & Equipment industry, where returns on equity and assets are generally expected to be positive and in the low single digits. The company reported a net loss of SEK -17.71 million, with operating income also negative at SEK -17.84 million. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic downturns or regulatory changes that could impact the company's primary market. The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest period and no forward-looking guidance provided in the available data. The negative operating and net income figures suggest the company is not currently generating value for shareholders and may require significant restructuring or capital injections to achieve profitability. Risk factors include the company's negative cash flow and lack of long-term debt, which may limit its ability to fund expansion or R&D initiatives. The risk assessment indicates low dilution potential, but the liquidity risk is rated as low, suggesting the company has sufficient cash reserves to meet short-term obligations. No immediate filing-based liquidity or dilution flags were detected, but the negative operating cash flow and free cash flow raise concerns about long-term sustainability. Recent events include the latest financial filing, which shows continued losses and negative cash flows. No recent earnings call transcripts or press releases were available to provide additional context on the company's strategic direction or operational performance.

30-day price · BIOEX(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBioextrax AB publ
TickerBIOEX.ST
SectorIndustrials
BusinessIndustrial & Commercial Services
Industry groupIndustrial & Commercial Services
IndustryEnvironmental Services & Equipment
AI analysis

Business. Bioextrax AB publ provides industrial services focused on environmental solutions, including waste management and recycling technologies.

Classification. Bioextrax is classified under the Environmental Services & Equipment industry within the Industrial & Commercial Services business sector, with a confidence level of 0.92.

Bioextrax operates with a debt-free capital structure, as evidenced by a debt-to-equity ratio of 0.0. The company holds SEK 3.93 million in cash and equivalents, but its operating cash flow is negative at SEK -26.05 million, indicating a reliance on external financing or asset sales to fund operations. The current ratio of 1.58 suggests the company can cover its short-term liabilities with its current assets, but the negative free cash flow of SEK -16.73 million raises concerns about long-term liquidity. Profitability metrics are severely negative, with a return on equity of -83.46% and a return on assets of -71.6%. These figures are well below the typical thresholds for sustainability in the Environmental Services & Equipment industry, where returns on equity and assets are generally expected to be positive and in the low single digits. The company reported a net loss of SEK -17.71 million, with operating income also negative at SEK -17.84 million. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic downturns or regulatory changes that could impact the company's primary market. The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest period and no forward-looking guidance provided in the available data. The negative operating and net income figures suggest the company is not currently generating value for shareholders and may require significant restructuring or capital injections to achieve profitability. Risk factors include the company's negative cash flow and lack of long-term debt, which may limit its ability to fund expansion or R&D initiatives. The risk assessment indicates low dilution potential, but the liquidity risk is rated as low, suggesting the company has sufficient cash reserves to meet short-term obligations. No immediate filing-based liquidity or dilution flags were detected, but the negative operating cash flow and free cash flow raise concerns about long-term sustainability. Recent events include the latest financial filing, which shows continued losses and negative cash flows. No recent earnings call transcripts or press releases were available to provide additional context on the company's strategic direction or operational performance.
Key takeaways
  • Bioextrax is operating at a significant loss, with a return on equity of -83.46% and a return on assets of -71.6%.
  • The company has no long-term debt but is generating negative cash flows, raising concerns about long-term liquidity.
  • Revenue is concentrated in a single segment, with no geographic diversification disclosed.
  • No immediate dilution or liquidity flags were detected, but the company's financial performance suggests a need for strategic intervention.
  • --
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$757.0k
Gross profit-$501.0k
Operating income-$17.8M
Net income-$17.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$26.0M
CapEx-$152.0k
Free cash flow-$16.7M
Total assets$24.7M
Total liabilities$3.5M
Total equity$21.2M
Cash & equivalents$3.9M
Long-term debt$0.00
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$21.2M
Net cash$3.9M
Current ratio1.6
Debt/Equity0.0
ROA-71.6%
ROE-83.5%
Cash conversion1.5%
CapEx/Revenue-20.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Industrial Services · cohort 626 companies
MetricBIOEXActivity
Op margin-2356.5%6.0% medp25 -2.1% · p75 13.4%bottom quartile
Net margin-2338.8%4.1% medp25 -2.2% · p75 10.8%bottom quartile
Gross margin-66.2%28.8% medp25 19.4% · p75 44.6%bottom quartile
R&D / revenue2.7% medp25 2.4% · p75 3.1%
CapEx / revenue-20.1%-5.0% medp25 -12.8% · p75 -1.9%bottom quartile
Debt / equity0.0%26.4% medp25 5.2% · p75 66.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 21:36 UTC#e7d873a7
Market quoteclose SEK 2.49 · shares 0.05B diluted
no public URL
2026-05-04 22:18 UTC#5a5515b1
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:24 UTCJob: 4624715c